Current HIV ResearchPub Date : 2024-11-12DOI: 10.2174/011570162X317921241009083357
Zhen-Hua Li, Bao-Jiang Xie, Wei Yi, Li Li, Ya-Xian Wei, Nuo Yi, Li-Hong Lu
{"title":"Holter Monitoring Analysis of Women Infected with the Human Immunodeficiency Virus.","authors":"Zhen-Hua Li, Bao-Jiang Xie, Wei Yi, Li Li, Ya-Xian Wei, Nuo Yi, Li-Hong Lu","doi":"10.2174/011570162X317921241009083357","DOIUrl":"https://doi.org/10.2174/011570162X317921241009083357","url":null,"abstract":"<p><strong>Objective: </strong>The aim of the study was to assess the clinical features of women infected with the human immunodeficiency virus (HIV) using Holter monitoring.</p><p><strong>Methods: </strong>Thirty-five female patients infected with HIV using a Holter monitor at the Ditan Hospital were retrospectively analyzed.</p><p><strong>Results: </strong>In terms of basic rhythms, there were 30 cases of sinus rhythm, 27 cases of ventricular premature beat, 26 cases of supraventricular premature beat, 12 cases of mild reduction of HRV, 9 cases of normal heart rate variability (HRV), 8 cases of supraventricular tachycardia, 5 cases of abnormal ST-segment changes and 2 cases of sinus bradycardia 2 cases of paroxysmal atrial fibrillation 2 cases of junctional escape rhythm. There was only one case in each of the following ECG changes: persistent atrial fibrillation, sinus tachycardia, couplet supraventricular premature beats, accelerated idioventricular rhythm, sinoatrial block, second-degree Mobitz type I atrioventricular block, second-degree Mobitz type II atrioventricular block, complete right bundle branch block, T-wave abnormality, and significant reduction of HRV.</p><p><strong>Conclusion: </strong>The Holter monitor can show more changes in the electrocardiogram (ECG) of HIV-- positive patients, particularly significant ECG abnormalities, such as paroxysmal atrial fibrillation, and can direct early clinical treatment to serious adverse results.</p>","PeriodicalId":10911,"journal":{"name":"Current HIV Research","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Effects of Resveratrol in a Randomized Clinical Trial on Drug-Induced Hyperlipidemia and Psychiatric Factors in People Living with HIV.","authors":"Bahar Ahmadi-Mousavi, Somayyeh Karami-Mohajeri, Fatemeh Dabaghzadeh, Motahareh Soltani, Zohreh Oghabian, Hamid Sharifi","doi":"10.2174/011570162X301403241104043813","DOIUrl":"https://doi.org/10.2174/011570162X301403241104043813","url":null,"abstract":"<p><strong>Introduction: </strong>People living with HIV (PLHIV) suffer from a range of consequences related to infection, including hyperlipidemia and neurologic and sleep disorders. Supplements containing phenolic compounds with high antioxidant properties can reduce these side effects. Resveratrol is a phenolic compound that improves the symptoms of diabetes, cancer, and viral infections. This study aimed to evaluate the effects of resveratrol on hyperlipidemia and neurological problems in PLHIV in Iran.</p><p><strong>Method: </strong>In this double-blind, randomized clinical trial, 41 PLHIV were randomly assigned to two groups: a placebo group (n=21) and a resveratrol group (n=20). Triglyceride and cholesterol levels were determined for all the subjects before and one month after they used the medication. Additionally, standard questionnaires were used to evaluate the quality of sleep, stress, depression, and quality of life of the participants. The data were analyzed via analysis of covariance in Stata 17.0.</p><p><strong>Results: </strong>The study population did not significantly differ in terms of age (p=0.49), sex (p=0.09), marital status (p=0.90), level of education (p=0.90), duration of HIV infection (p=0.54), or mode of HIV transmission (p=0.51). The administration of resveratrol did not affect psychological parameters or blood cholesterol (p=0.091) or triglyceride (p=0.932) levels.</p><p><strong>Conclusion: </strong>The administration of resveratrol did not affect cholesterol or triglyceride levels or the rates of depression, anxiety, sleep quality, or quality of life in PLHIV. The resveratrol supplementation in a large-scale clinical study involving more patients for a longer course of treatment may have had more significant effects on the serum levels of lipids and psychological factors.</p>","PeriodicalId":10911,"journal":{"name":"Current HIV Research","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}